NOVN enters the first week of September in a comfortable position — up nearly 5% on the week to CHF 129.58, outrunning most of its large-cap pharma peers while short sellers show little appetite to press the other way.
The lending market is about as relaxed as it gets for a stock of this size. Borrow availability is effectively unlimited, with the pool of shares available to lend running at multiples of any conceivable short position — the 52-week low availability reading never dropped below 1,189% of outstanding short interest. Cost to borrow is just 0.66%, essentially the risk-free rate for locating shares. There was a brief spike to around 1.96% in mid-August, but that unwound quickly and conditions have since normalised. The ORTEX short score sits at 25.97 — in the 95th percentile for low short conviction — and has barely moved over the past two weeks, drifting up less than 0.2 points. This is not a stock that bears are building positions in.
The week's relative outperformance looks even more pronounced against its peer group. AZN managed a gain of just 0.3% on the week while GSK slipped 0.4%. posted a more comparable 2.7% gain, and actually fell 2.1%. was the notable laggard, dropping 2.7% on the week and shedding a further 4.6% on Friday alone. Novartis's 5% weekly move places it near the top of its peer group without any obvious single-stock catalyst — which in pharma often means macro and currency tailwinds rather than anything company-specific.
On the Street, there are no recent analyst changes in the data. The consensus mean price target is CHF 155.01, implying roughly 20% upside from the current CHF 129.58 close — a meaningful gap that suggests the buy-side broadly sees the stock as undervalued at current levels. Valuation multiples have been drifting gently lower over the past 30 days: the P/E has eased to 16.4x (down from roughly 17.2x a month ago), and EV/EBITDA has compressed to 13.0x. Neither move is dramatic, but the direction reflects the stock re-rating higher on price while earnings estimates hold firm. The dividend factor score ranks in the 94th percentile — a nod to the yield's role as a valuation floor for income-sensitive holders, though the dividend data in the snapshot predates 2023 and the current yield level should be verified against the latest declared amount.
Institutional ownership tells a broadly constructive story. UBS Asset Management holds 6.2% of shares and added 1.6 million shares in the most recently reported period. Massachusetts Financial Services added over 3.2 million shares through June. Fisher Asset Management added 1.6 million. On the other side, Norges Bank trimmed a modest 244,000 shares. The net direction from the larger active managers tilts toward accumulation. Insider data from the Swiss vendor feed shows a cluster of executive committee sales dating back to February, with the most recent disclosed trades on 27 July — a combined 11,304 shares sold at around CHF 129. The 90-day net figure, however, is a positive 18,133 shares, suggesting the aggregate insider position over the period is marginally net buying despite the individual sale disclosures.
The next scheduled earnings event is 27 October. At the last two prints, the stock moved modestly: up 1.8% the day after the July 2026 release and extending to nearly 6% over five days, while the April 2026 result produced a small 0.6% decline on the day and essentially no net move over the following week. That pattern — limited earnings volatility — fits the positioning picture: with borrow effectively free, no short squeeze risk, and a peer group that is broadly softer on the week, the more interesting question heading into October is whether the 20% gap between price and consensus target starts to close, or whether the Street trims estimates to meet a stock that has already moved.
See the live data behind this article on ORTEX.
Open NOVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
